Binex Co.

Busan, South Korea

Binex Co.

Busan, South Korea
SEARCH FILTERS
Time filter
Source Type

To join hands with leading Korean industry player in Developing into an international biopharmaceutical enterprise Tongfang Kontafarma Holdings Limited ("Tongfang Kontafarma" or the "Group"; stock code: 1312.hk), today announced the proposed 29% stake acquisition of Binex Co. Ltd. ("Binex" or the "Target Company"; stock code: 053030.ks), a Korea-listed company engaged in the manufacturing and selling of pharmaceuticals mainly in Korea. On 29 November 2016 (before trading hours), Tongfang Kontafarma entered into a share subscription agreement with Binex and its majority shareholders, pursuant to which the Group has conditionally agreed to subscribe, and the Target Company has conditionally agreed to issue to the Group, the subscription shares, representing (i) approximately 29% of the total issued share capital of the Target Company as enlarged by the subscription shares immediately upon completion of the subscription; and (ii) approximately 28% of the total issued share capital of the Target Company as enlarged by the subscription shares and assuming that all the outstanding convertible bonds and employees share options of the Target Company are fully converted and exercised. Upon completion, Binex will have a total of 7 directors, 4 of which will be nominated by Tongfang Kontafarma and the remaining 3 will be nominated by the Target Company's original majority shareholders, which will then hold approximately 7.60% of the total issued share capital as enlarged by the subscription shares. The Target Company will be regarded as a non-wholly owned subsidiary of the Group and the financial results, assets and liabilities of the Target Group will be consolidated into the accounts of the Group upon completion. The subscription will constitute a very substantial acquisition of the Group under the HKEx Listing Rules and is therefore subject to reporting, announcement and shareholders' approval requirements. Mr. Huang Yu, Chairman of the Group, said, "Tongfang Kontafarma will cooperate with Binex to build an international biopharmaceutical industry base. Binex will draw from its extensive experience in building, operating and managing biopharmaceutical production plants to provide technical guidance and comprehensive solutions for the factory project, as well as assign its experienced technical, management and operational staff to work in China to aid the construction of the new factory and later-stage management and operation. We have full confidence in cooperating with Binex." Binex is a leading Korean biopharmaceutical enterprise and the second largest biopharmaceutical CMO (Contract Manufacturing Organization) company in the country after Samsung. It owns two biopharmaceutical factories, which have passed Korean GMP certification, the European Qualified Person (QP) audit and the even more stringent on-site audits by international pharmaceutical giants such as Merck Sereno, MSD and Sanofi. It has completed over 200 batches of biopharmaceutical products, with the support of its full range of world-class GMP manufacturing facilities and strong industrialization ability. It has a pool of products which have completed or are undergoing stage II & III clinical trials in Japan, the U.S. and Europe. In particular, it has one drug, Remicade biosimilar, that has completed clinical III trial in Japan and is awaiting final approval from PMDA (Pharmaceuticals and Medical Device Agency (Japan)). Final approval is expected in the first half of 2017. Mr. Huang concluded, "Tongfang Kontafarma has been cooperating with a few dozen experienced scientists specializing in biopharmaceutical R&D from the School of Pharmaceutical Sciences, School of Medicine and School of Life Sciences of Tsinghua University to build a world leading R&D platform for innovative biomedicines. It will apply Binex's leading biopharmaceutical technologies and experience to build an "industry-academia-research" integrated biopharmaceutical industry chain. This latest acquisition will allow the Group to establish presence in the international biopharmaceutical sector, as well as tap Binex's rich international CMO customer resources and business experience to speed up international authorization for the Group's innovative biomedicines under development and foster development of the international CMO business of its industrial base. The acquisition will give the Group a solid foundation to develop into a world leading international biopharmaceutical company that focuses on innovation and industrialization. We are excited about the proposed acquisition of Binex as it represents a key milestone of Tongfang Kontafarma's development into a regional pharmaceutical and healthcare enterprise." About Tongfang Kontafarma Holdings Limited Tongfang Kontafarma Holdings Limited ("Tongfang Kontafarma" or the "Group"; stock code: 1312.hk) is engaged principally in the cement business in the PRC. As announced in recent financial reports, in addition to pursuing the Group's own strategies to improve its existing businesses, the Group will actively explore medical, pharmaceutical and health industry business and other investment opportunities, in order to enhance its income and prepare for the Group's future development. In 2016, the Group acquired 60% equity interest in Beijing Ziguang Pharmaceutical Co., Ltd., a sino-foreign joint venture enterprise established in the PRC principally engaged in, the manufacturing and sales of prescription drugs, including injection powder, tablets, capsules, ointments, traditional Chinese medicine patent prescriptions, synthetic drugs, preparations, biochemical drugs and other biochemical products. Contact: Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS


Chang H.N.,Korea Advanced Institute of Science and Technology | Kim N.-J.,Korea Advanced Institute of Science and Technology | Kim N.-J.,Samsung | Kang J.,Korea Advanced Institute of Science and Technology | And 9 more authors.
Bioprocess and Biosystems Engineering | Year: 2011

We carried out the first simulation on multi-stage continuous high cell density culture (MSC-HCDC) to show that the MSC-HCDC can achieve batch/fed-batch product titer with much higher productivity to the fed-batch productivity using published fermentation kinetics of lactic acid, penicillin and ethanol. The system under consideration consists of n-serially connected continuous stirred-tank reactors (CSTRs) with either hollow fiber cell recycling or cell immobilization for high cell-density culture. In each CSTR substrate supply and product removal are possible. Penicillin production is severely limited by glucose metabolite repression that requires multi-CSTR glucose feeding. An 8-stage C-HCDC lactic acid fermentation resulted in 212.9 g/L of titer and 10.6 g/L/h of productivity, corresponding to 101 and 429% of the comparable lactic acid fed-batch, respectively. The penicillin production model predicted 149% (0.085 g/L/h) of productivity in 8-stage C-HCDC with 40 g/L of cell density and 289% of productivity (0.165 g/L/h) in 7-stage C-HCDC with 60 g/L of cell density compared with referring batch cultivations. A 2-stage C-HCDC ethanol experimental run showed 107% titer and 257% productivity of the batch system having 88.8 g/L of titer and 3.7 g/L/h of productivity. MSC-HCDC can give much higher productivity than batch/fed-batch system, and yield a several percentage higher titer as well. The productivity ratio of MSC-HCDC over batch/fed-batch system is given as a multiplication of system dilution rate of MSC-HCDC and cycle time of batch/fed-batch system. We suggest MSC-HCDC as a new production platform for various fermentation products including monoclonal antibody. © 2010 Springer-Verlag.


Lee K.S.,Changwon National University | Lee K.S.,Binex Co. | Shim J.S.,Ajou University | Paik M.J.,Sunchon National University | And 4 more authors.
Biotechnology and Bioprocess Engineering | Year: 2015

Human bone marrow-derived mesenchymal stem cells (hMSCs) are capable of self-renewal and differentiation into various tissue lineages, attracting attention as tools for use in cell therapy. However, hMSCs have very poor proliferative capacity and a short life span in culture. To overcome this problem, we expressed the T antigen of SV40 in hMSCs because it is known to have the ability to elevate the growth rate of various primary animal cells. We obtained several hMSCs lines (hMSCs-T) known for stable expression of T antigen. Cells expressing T antigen proliferated on the monolayer of hMSCs, forming high density foci. hMSCs-T showed changed morphology and improved growth rate and life span, and demonstrated preservation of the potential for differentiation into osteoblasts. In addition, hMSCs-T did not proliferate in soft agar culture, indicating that the cells did not transform into tumor cells. In order to evaluate metabolic change of amino acids in hMSCs-T compared to primary hMSCs, we investigated altered amino acids (AA) with gas chromatography-mass spectrometry (GC-MS) in selected ion monitoring (SIM) mode (GC-SIM-MS). A total of 14 AAs were positively measured. Results from the Student’s t-test on the hMSCs group mean of the hMSCs-T group showed significantly elevated levels of glycine, proline, pipecolic acid, aspartic acid, lysine and tryptophan, whereas valine, leucine and isoleucine as branched-chain amino acids (BCAAs), and phenylalanine showed a significant decrease. Altered AAs metabolic pattern in the hMSCs-T may explain the disturbance of AA metabolism related to the expression of SV40 T antigen in hMSCs. © 2015, The Korean Society for Biotechnology and Bioengineering and Springer-Verlag Berlin Heidelberg.


Kim J.C.,Sejong University | Kim J.C.,Binex Co. | Seong J.H.,Sejong University | Lee B.,PBS Biotech Inc. | And 3 more authors.
Biotechnology and Bioprocess Engineering | Year: 2013

Single use culture systems are a tool in research and biotechnology manufacturing processes and are employed in mammalian cell-based manufacturing processes. Recently, we characterized a novel bioreactor system developed by PBS Biotech. The Pneumatic Bioreactor System™ (PBS) employs the Air-wheel™, which is a mixing device similar in structure to a water wheel but is driven by the buoyant force of gas bubbles. In this study, we investigated the physical properties of the PBS system, with which we performed biological tests. In 2 L PBS, the mixing times ranged from 6 (30 rpm, 0.175 vvm) to 15 sec (10 rpm, 0.025 vvm). The kLa value reached upto 7.66/h at 0.5 vvm, even without a microsparger, though this condition is not applicable for cell cultures. Also, when a 10 L PBS equipped with a microsparger was evaluated, a kLa value of upto approximately 20/h was obtained particularly in mild cell culture conditions. We performed cultivation of Chinese hamster ovary (CHO) cells in 2 and 10 L PBS prototypes. Results from the PBS were compared with those from an Erlenmeyer flask and conventional stirred tank type bioreactor (STR). The maximum cell density of 10.6 × 106 cells/mL obtained fromthe 2 L PBSwas about 2 times higher than that from the Erlenmeyer flask (5.6 × 106 cells/mL) andwas similar to the STR (9.7 × 106 cells/mL) when the CHO-S cells were cultured. These results support the general suitability of the PBS system using pneumatic mixing for suspension cell cultivation as a novel single-use bioreactor system. © 2013 The Korean Society for Biotechnology and Bioengineering and Springer-Verlag Berlin Heidelberg.


Son J.H.,Binex Co. | Heo Y.J.,Binex Co. | Park M.Y.,Pusan National University | Kim H.H.,Pusan National University | Lee K.S.,Pusan National University
Cryobiology | Year: 2010

The conditions for cryopreservation of CD34+ hematopoietic stem cells (HSC) from umbilical cord blood (UCB) were optimized with a new cryo-medium containing 10% ethylene glycol (EG) and 2% dimethyl sulfoxide (Me2SO) using a controlled-rate freezing (CRF) method. After the cryopreservation of mononuclear cells (MNC) from UCB, recoveries of MNC, CD34+ cells, and total colony-forming units (CFU) were significantly improved compared to those in the control cryo-medium containing 10% Me2SO and 2% Dextran-40 (P<0.05). This study shows that the new cryo-medium and CRF method provide better recoveries of MNC, HSC and total CFU than the control cryo-medium and isopropylalcohol freezing (IPA) method. Therefore, this cryo-medium, combined with the CRF method, is valuable for optimizing cryopreservation conditions for HSC from UCB to obtain satisfactory HSC recovery. © 2010 Elsevier Inc.


Bae J.-H.,Pusan National University | Kim J.-Y.,Pusan National University | Kim M.-J.,Pusan National University | Chang S.-H.,Pusan National University | And 7 more authors.
Journal of Immunotherapy | Year: 2010

It is known that treatments with heat shock, some anticancer drugs, and ionizing radiation increase the expression of heat-shock proteins (HSPs) and natural killer group 2D (NKG2D) ligands in tumor cells. The increased HSPs may make the tumor cells resistant to apoptosis and reduction of HSPs may make the tumor cells more susceptible to natural killer (NK)-cell mediated lysis of tumor cells. In this study, we investigated whether quercetin which has inhibitory activities against heat-shock factor, protein kinase C, nuclear factor-κB, and phosphatidyl inositol 3-kinase, can modulate the expression of NKG2D ligands and suppress the HSPs in tumor cells. The results of this study showed that quercetin significantly induced the expression of several NKG2D ligands including major histocompatibility complex class I-related chain B, UL16-binding protein 1, and UL16-binding protein 2 in K562, SNU1, and SNU-C4 cells. The quercetin-treated K562, SNU1, and SNU-C4 cells showed an enhanced susceptibility to NK-92 cells through induction of NKG2D ligands. This increased expression of NKG2D ligands seemed to be due to the inhibition of the nuclear factor-κB and phosphatidyl inositol 3-kinase pathways. The findings of this study suggest that the induced NKG2D ligands with the decrease of HSP70 protein by quercetin may provide an attractive strategy to improve the effectiveness of NK cell-based cancer immunotherapy. Copyright © 2010 by Lippincott Williams & Wilkins.


Lim J.I.,Yonsei University | Lim K.-J.,Yonsei University | Lim K.-J.,Binex Co. | Na Y.-C.,Korea Basic Science Institute | Lee Y.-K.,Denforus Co.
Journal of Bioscience and Bioengineering | Year: 2010

Protease inhibitors have been usually isolated through a number of steps using various chromatographical methods, which are time consuming and tedious. In this report, an efficient and low-cost acrylamide affinity gel electrophoresis method for the detection and isolation of chymotrypsin inhibitor from a crude extract was studied. The affinity gel was obtained by immobilization of chymotrypsin on 5% (w/v) poly acrylamide-oleic acid gel, and the immobilized chymotrypsin showed high stability under varied concentrations of urea (0 to 8. M), pH (4 to 10) and temperature (30 to 80°C). The affinity gel made of immobilized chymotrypsin was applied to polyacrylamide affinity gel electrophoresis and reverse electrode electro-elution using a modified commercial electrophoresis kit. Polyacrylamide affinity gel electrophoresis method showed higher isolation efficiency for chymotrypsin inhibitor from Ganoderma lucidum crude extract than a chromatographical method. Specific activity and yield of chymotrypsin inhibitor increased around 2.3-folds and 1.4-folds, respectively, compared with a chromatographical method. Also, two isomers of the inhibitor could be isolated by this method. Therefore, this method can be applied for the detection and isolation of bio-active molecules as a fast and economical method. © 2010 The Society for Biotechnology, Japan.


Um S.-J.,Dong - A University | Choi Y.J.,Pusan National University | Shin H.-J.,Pusan National University | Son C.H.,Binex Co. | And 12 more authors.
Lung Cancer | Year: 2010

Background: A dendritic cell vaccine has been developed as a novel strategy for generating antitumor immunity in the treatment of cancer. The purpose of this study was to assess the maximal tolerated dose, safety, and immunologic response of a new dendritic cell vaccine (DC-Vac) into which tumor lysate was loaded by electroporation and pulse in patients with advanced non-small cell lung cancer (NSCLC). Patients and methods: Fifteen patients with inoperable stage III or IV NSCLC were assigned to cohorts that received 3, 6, or 12×106 DC-Vac intradermally 3 times at 2 week intervals. We also evaluated immunologic and tumor responses. Results: The maximum dose of DC-Vac (12×106) was shown to be safe. In 5 of 9 patients, the vaccine resulted in increased interferon (IFN)-γ production by CD8+ cells after exposure to tumor lysate. Additionally, there were mixed responses which do fulfill progressive disease definition but demonstrate some clinical benefit in two patients. Conclusion: The administration of tumor lysate-loaded autologous dendritic cells by electroporation and pulse was non-toxic and induced immunologic responses to tumor antigens. The two mixed tumor responses which were achieved may represent a potential benefit of this new DC-Vac. © 2010 Elsevier Ireland Ltd.


PubMed | Binex Co.
Type: Journal Article | Journal: Cryobiology | Year: 2010

The conditions for cryopreservation of CD34(+) hematopoietic stem cells (HSC) from umbilical cord blood (UCB) were optimized with a new cryo-medium containing 10% ethylene glycol (EG) and 2% dimethyl sulfoxide (Me(2)SO) using a controlled-rate freezing (CRF) method. After the cryopreservation of mononuclear cells (MNC) from UCB, recoveries of MNC, CD34(+) cells, and total colony-forming units (CFU) were significantly improved compared to those in the control cryo-medium containing 10% Me(2)SO and 2% Dextran-40 (P<0.05). This study shows that the new cryo-medium and CRF method provide better recoveries of MNC, HSC and total CFU than the control cryo-medium and isopropylalcohol freezing (IPA) method. Therefore, this cryo-medium, combined with the CRF method, is valuable for optimizing cryopreservation conditions for HSC from UCB to obtain satisfactory HSC recovery.

Loading Binex Co. collaborators
Loading Binex Co. collaborators